NCT04626921 - A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 22, 2020

Primary Completion Date

May 29, 2023

Study Completion Date

September 6, 2023

Conditions

Relapsing Multiple Sclerosis

Interventions

DRUG

CNM-Au8

30 mg of CNM-Au8

Trial Locations (5)

Sydney Brain Mind Centre, Camperdown

John Hunter Hospital, New Lambton Heights

The Alfred Centre Department of Neuroscience, Melbourne

Princess Alexandra Hospital, Woolloongabba

Menzies Institute for Medical Research, Hobart